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Abstract 
Background: Intracellular metabolism of glucocorticoid hormones plays an important role in the pathogenesis 
of metabolic syndrome and regulates, among many physiological processes, collagen metabolism in skin. At the 
peripheral level the concentration of active glucocorticoids is mainly regulated by the 11β-hydroxysteroid dehydro-
genase 1 (11β-HSD1) enzyme, involved in the conversion of cortisone into the biologically active hormone cortisol. 
Cortisol interacts with the glucocorticoid receptor and regulates the expression of different classes of genes within 
the nucleus. Due to its implication in glucocorticoid metabolism, the inhibition of 11β-HSD1 activity has become a 
dominant strategy for the treatment of metabolic syndrome. Moreover, inhibitors of this target enzyme can be used 
for development of formulations to counteract skin ageing. Here we present the construction of two yeast cell based 
assays that can be used for the screening of novel 11β-HSD1 inhibitors.
Results: The yeast Saccharomyces cerevisiae is used as a host organism for the expression of human 11β-HSD1 as well 
as a genetically encoded assay system that allows intracellular screening of molecules with 11β-HSD1 inhibitory activ-
ity. As proof of concept the correlation between 11β-HSD1 inhibition and fluorescent output signals was successfully 
tested with increasing concentrations of carbenoxolone and tanshinone IIA, two known 11β-HSD1 inhibitors. The first 
assay detects a decrease in fluorescence upon 11β-HSD1 inhibition, whereas the second assay relies on stabilization 
of yEGFP upon inhibition of 11β-HSD1, resulting in a positive read-out and thus minimizing the rate of false posi-
tives sometimes associated with read-outs based on loss of signals. Specific inhibition of the ABC transporter Pdr5p 
improves the sensitivity of the assay strains to cortisone concentrations by up to 60 times.
Conclusions: Our yeast assay strains provide a cost-efficient and easy to handle alternative to other currently avail-
able assays for the screening of 11β-HSD1 inhibitors. These assays are designed for an initial fast screening of large 
numbers of compounds and enable the selection of cell permeable molecules with target inhibitory activity, before 
proceeding to more advanced selection processes. Moreover, they can be employed in yeast synthetic biology plat-
forms to reconstitute heterologous biosynthetic pathways of drug-relevant scaffolds for simultaneous synthesis and 
screening of 11β-HSD1 inhibitors at intracellular level.
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Background
Glucocorticoids, such as cortisone and cortisol in 
human, are stress hormones with a vital role in regula-
tion of metabolic and defence responses. They exert a 
role in many mammalian biological processes including 
regulation of energy metabolism, immune and inflam-
matory responses, cardiovascular homeostasis and the 
body’s responses to stress [1–3]. Several studies have also 
underlined the role of glucocorticoids in regulation of 
collagen homeostasis and wound healing processes [4, 5]. 
Research performed over the past 20 years has shed light 
on the involvement of glucocorticoid metabolism in the 
pathogenesis of obesity, a major risk factor for the meta-
bolic syndrome, a collection of disorders including insu-
lin resistance, dyslipidemia and hypertension [6].
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A key step in the molecular elucidation of these biolog-
ical processes and conditions has been the demonstration 
that glucocorticoid receptor activation in target tissues is 
not determined exclusively by circulating glucocorticoids 
but also by intra-cellular interconversion of active and 
inactive forms of the steroids [7]. Identification of this 
mechanism for local regulation of glucocorticoid action 
has prompted the concept that tissue-specific glucocor-
ticoid excess, in the face of normal circulating concen-
trations, may contribute to metabolic syndromes [8] and 
plays an important role in the skin ageing process, reduc-
ing collagen metabolism and promoting skin atrophy [5].
The production of active glucocorticoid hormones at 
the intracellular level is regulated by the two hydroxyster-
oid dehydrogenase enzyme isoforms 11β-hydroxysteroid 
dehydrogenase 1 (11β-HSD1) and 11β-HSD2, micro-
somal enzymes belonging to the family of short chain 
dehydrogenases/reductases. The 11β-hydroxysteroid 
dehydrogenases (11β-HSDs) catalyse the interconversion 
of inactive cortisone to active cortisol and vice versa [9]. 
11β-HSD2 is predominantly expressed in mineralocor-
ticoid target tissues, such as salivary glands, colon and 
kidneys. Its role is to protect the non-selective mineralo-
corticoid receptor from the unspecific binding from cor-
tisol, catalysing its conversion to cortisone [10].
11β-HSD1 acts in  vivo mainly as a reductase, con-
verting cortisone into the biologically active steroid 
cortisol in a NADPH dependent manner [11]. The 
intracellular co-localization of 11β-HSD1 with hexose-
6-phosphate dehydrogenase has a fundamental role in 
providing NADPH as cofactor driving the reductase 
activity of 11β-HSD1, rather than the dehydrogenase 
activity [12]. In  vitro 11β-HSD1 has a Km in the µM 
range for both cortisone and cortisol [13]. The enzyme 
is mostly expressed in liver, fat, gonadal tissue and the 
central nervous system, where it amplifies local gluco-
corticoid concentrations [9]. Inside the cells cortisol 
interacts with the cytosolic glucocorticoid receptor 
(GR), prompting receptor dimerization and transloca-
tion to the nucleus. Receptor dimers then bind to the 
glucocorticoid response element (GRE) in target genes, 
leading to regulation of their transcription [14]. The 
main actions of GR-mediated glucocorticoid stimula-
tion include anti-inflammatory and immunosuppressive 
effects, the regulation of the metabolism of glucose, and 
the differentiation of adipose tissue [15].
Genetic models developed in mice suggested that 
overexpression of 11β-HSD1 is a factor involved in the 
development of central obesity and type 2 diabetes [16]. 
Moreover 11β-HSD1 knock-out mice showed enhanced 
glucose tolerance and improved lipid and lipoprotein 
profiles [17]. Increased cortisol levels due to overexpres-
sion of 11β-HSD1 in aged skin were demonstrated to be 
common features of mammalian ageing processes. Con-
versely 11β-HSD1 knock-out mice showed improved age-
induced dermal atrophy and structural disorganization 
with increased collagen density and faster wound healing 
processes [18].
In the light of this evidence, specific inhibition of 11β-
HSD1 has been proposed as a crucial strategy for treat-
ment of metabolic syndrome and for the stimulation of 
collagen organization and wound healing in elderly and 
diabetic individuals [15, 18, 19].
In recent years many research groups have developed 
different strategies for the discovery of new candidate 
molecules exhibiting selective inhibitory effects towards 
human 11β-HSD1. Most approaches for selection of can-
didate inhibitors use liver microsomes or recombinant 
mammalian cell lines expressing 11β-HSD1. Analyses 
of cortisone and cortisol contents are performed using 
Liquid Chromatography-Mass Spectrometry [20]. Other 
strategies involve the stable heterologous expression 
of 11β-HSD1 combined with β-galactosidase reporter 
constructs under control of glucocorticoid response ele-
ments [21]. Even though these strategies represent pow-
erful tools to filter and select active compounds from 
large libraries of molecules, they often require the use of 
hazardous radioactive substances or the use of colorimet-
ric materials that can interfere with the tested molecules. 
Moreover, they require expensive instrumentation and 
expertise.
The baker’s yeast Saccharomyces cerevisiae has 
emerged in the last decades as a powerful organism for 
the study of many human target enzymes. The deep 
genetic information available on this system has allowed 
it to become an increasingly popular model for phar-
macological and/or drug discovery studies that can be 
used to analyse the effects of drugs in vivo during initial 
stages, before tests are performed in mammalian systems 
[22, 23]. Compared to higher eukaryotes, yeast cells are 
more economical, easier to grow and can be genetically 
manipulated with greater ease. Furthermore, yeast cells 
are generally freely accessible to small molecules and can 
even be engineered to increase permeability if necessary. 
Hence, the availability of well-established genomic meth-
ods and resources makes budding yeast an extremely val-
uable asset for the screening of molecules with possible 
pharmaceutical applications [24].
In order to develop an efficient and reliable alterna-
tive for screening large numbers of candidate inhibitors 
of 11β-HSD1, two yeast strains were constructed, func-
tionally co-expressing the murine GR and the human 
11β-HSD1 enzyme. In these strains, cortisone is taken 
up from the medium and converted—through the action 
of 11β-HSD1—to cortisol that then binds to the GR. 
In each of the two strains, the cortisol/GR activates a 
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specific gene whose expression leads to the modulation 
of a yEGFP fluorescent signal. In one strain, the signal 
is converted into a positive output (stable fluorescence) 
in the presence of an 11β-HSD1 inhibitor; in the other 
strain inhibition of 11β-HSD1 leads to a loss of signal. To 
increase sensitivity of the assay systems the yeast multi 
drug efflux system and in particular the function of the 
yeast Pdr5 ATP-binding cassette (ABC) transporter in 
cortisone efflux was investigated and modified [25].
Results
Construction and validation of the assay strain RVY97
In order to develop a valid alternative to the biochemi-
cal and mammalian cell-based assays employed for the 
screening of 11β-HSD1 inhibitors we constructed the 
yeast strain RVY97, in which the activity of the 11β-
HSD1 enzyme can be easily assayed via fluorescent out-
put. The human 11β-HSD1 enzyme, heterologously 
expressed in yeast cells, reduces the cortisone provided in 
the growth medium, thereby converting it to cortisol, the 
active form of the steroid hormone. Cortisol binds to the 
glucocorticoid receptor, also heterologously expressed in 
yeast. The active complex translocates into the nucleus, 
promoting the expression of the yeast enhanced green 
fluorescent protein (yEGFP) via specific interaction with 
the glucocorticoid response element (GRE) upstream of 
the reporter gene. In this strain inhibition of 11β-HSD1 
causes a decrease of the green fluorescence (Fig. 1).
First, using flow cytometric analyses, the expression 
of yEGFP was assayed in strain RVY97 as a response to 
treatment with different cortisone concentrations, rang-
ing from 1.95 to 2000  μM (Fig.  2a). As expected, green 
fluorescence in the treated population increased, due to 
the action of 11β-HSD1, with increasing concentrations 
of cortisone, whereas in the absence of hormone no 
fluorescent signal was detected. Concentrations of cor-
tisone as low as 31.5  μM were effective, leading to the 
appearance of an unambiguous fluorescent signal con-
nected to the activity of 11β-HSD1. However, higher 
concentrations of cortisone were more desirable due to 
the stronger induction of reporter protein expression. 
Expression of yEGFP, driven by 11β-HSD1-dependent 
conversion of cortisone to cortisol, rose significantly 
upon treatment with a range of cortisone concentra-
tions between 60 and 500 μM. At higher concentrations 
a plateau of fluorescence intensity was reached (Fig. 2a). 
Of all hormone concentrations tested, 250 μM cortisone 
guaranteed the best compromise between intensity of the 
generated fluorescent signal and solubility of cortisone 
added to the yeast population. Flow cytometric analy-
sis and fluorescence microscope images of RVY97 cells 
treated with DMSO (negative control) and 250 μM corti-
sone are shown in Fig. 2b, c.
To address the validity of the assay for screening of 
putative 11β-HSD1 inhibitors, a series of experiments 
with a synthetic inhibitor of this enzyme were performed. 
RVY97 strain was incubated with cortisone in presence 
of carbenoxolone (CBX), a synthetic hemisuccinyl ester 
derivative of glycyrrhetinic acid. Carbenoxolone has 
been shown to exert potent but non-selective 11β-HSD1 
inhibitory activity and is frequently used as control in 
inhibition studies involving this target enzyme [26]. Car-
benoxolone behaves as a competitor of cortisone, binding 
to the active domain of 11β-HSD1 [27, 28].
In order to validate our assay with this molecule, dif-
ferent inhibitor concentrations ranging from 0.1 to 
3  μM were added to 1 million RVY97 cells together 
with 250  μM of cortisone. Increasing concentrations of 
Fig. 1 Schematic representation of the screening strain RVY97. In strain RVY97 the cortisone provided in the growth medium is converted to 
cortisol inside the cell by the enzyme 11β-HSD1. Cortisol binds the GR inducing assembly of an active complex that translocates to the nucleus. 
Through binding of the complex to the GRE, expression of the yEGFP reporter protein is triggered. In the presence of 11β-HSD1 inhibitors, cortisol is 
not produced, the GR is inactive and yEGFP not expressed
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carbenoxolone caused a gradual loss of yEGFP expres-
sion, indicating a decreased activity of 11β-HSD1 in the 
population with a complete absence of fluoresce at a con-
centration of 3 μM of inhibitor, most probably associated 
with the complete inhibition of the enzyme (Fig. 3).
Construction and validation of the assay strain RVY102
A robust cell-based screening assay relies on strong cor-
relation between an intracellular event and a univocal 
and easily detectable output. Screening systems with a 
positive readout guarantee the selection of hits from the 
analysis of large number of samples with minimum false 
positive results caused by unrelated intracellular events, 
such as impaired cellular viability or loss of an element 
of the assay system. To set up a more reliable assay for 
the screening of 11β-HSD1 inhibitors, a strain was con-
structed in which inhibition of 11β-HSD1 is connected 
to a positive fluorescent readout. In contrast to strain 
RVY97 where the activity of the enzyme is directly linked 
to the expression of a fluorescent reporter protein, in 
strain RVY102 the reduction of cortisone, driven by 
11β-HSD1, is combined with a tobacco etch virus (TEV) 
Fig. 2 Effect of cortisone on yEGFP expression in the strain RVY97. a Increased cortisone concentrations led to an increase of yEGFP expression in 
a concentration dependent manner. The treated RVY97 population (10,000 events) was analysed by flow cytometry and the results are expressed 
in percentage of RVY97 cells showing yEGFP fluorescence. Data shown represent means ± standard deviations of three independent experiments. 
b Fluorescence microscopy of strain RVY97 showed that cortisone treated cells displayed a strong fluorescent response to the hormone. c Flow 
cytometry analysis of the strain RVY97 cultivated with DMSO (upper panel) and 250 μM cortisone (lower panel) enabled quantitative analysis of the 
hormone response of this specific strain. The gate highlights the RVY97 population positive for the yEGFP expression. All analyses were carried out 
6 h after the addition of DMSO and cortisone, respectively. (a.u.): arbitrary unit
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protease induced protein instability (TIPI) mechanism 
[29] (Fig.  4a). This mechanism reversely combines the 
activity of the target enzyme to the stability of a constitu-
tively expressed reporter protein.
The TIPI strategy exploits the presence of a TEV cleav-
age site in a reporter protein in order to induce its deg-
radation. The reporter construct expresses a fluorescent 
fusion protein consisting of the red tandem dimer (td) 
Tomato, the TEV recognition site, an N-Degron destabi-
lizing sequence, the SF3b155381–424 protein domain and 
the yEGFP [29] (Fig. 4b).
As shown in Fig. 4a, the expression of the TEV protease 
under control of the glucocorticoid response element is 
driven by the active complex formed after specific bind-
ing of cortisol to the glucocorticoid receptor. Expression 
of TEV leads to cleavage of the reporter protein and to 
the exposure of a dormant N-degron sequence. This 
destabilizing stretch of amino acids causes the C-termi-
nal part of the reporter construct, including yEGFP, to 
undergo ubiquitination and proteasomal degradation 
[30]. The SF3b155381–424 protein domain binds strongly 
to the protein p14, fused to TEV, thus enhancing proces-
sivity of the protease [29]. The tdTomato red fluorescent 
protein is used for normalization purposes, since it does 
not undergo degradation upon TEV protease activity. 
On the other hand, the yEGFP reporter protein reverse 
monitors the TEV protease activity, as it is degraded 
upon TEV expression.
The described cascade in strain RVY102 directly cou-
ples the activity of 11β-HSD1 to yEGFP degradation. 
Inactivation of 11β-HSD1 caused by inhibitors, leads to 
stability of the reporter protein and detection of an intact 
green fluorescent signal in the population.
Functionality of assay strain RVY102 was tested by flow 
cytometric analyses. We monitored the green fluores-
cence response at different time points upon addition of 
different cortisone concentrations (from 125 to 2000 μM) 
(Fig.  5a). As expected, treatments with increasing con-
centrations of cortisone caused a gradual loss of yEGFP 
after 6 and 9 h of incubation indicating the reduction of 
cortisone to cortisol driven by 11β-HSD1 and the con-
sequent expression of TEV protease. Conversely, cells 
treated with DMSO maintained stable expression levels 
of the fluorescent fusion protein. Significant yEGFP deg-
radation was already observed upon 6 h of treatment with 
1000 and 2000 μM of cortisone, and degradation further 
increased upon after 9 h of incubation (Fig. 5a). Fluores-
cence microscopy images also showed the decrease in 
yEGFP signal, denoting a loss of green fluorescence upon 
cortisone treatment whereas td-Tomato fluorescence 
remained constant (Fig. 5b).
To select for the best experimental conditions many 
factors including cortisone solubility, time of incubation 
with the hormone and intensity of yEGFP fluorescence 
in response to treatments were experimentally evaluated. 
Finally, 6  h of incubation with 1000  μM cortisone were 
employed for the validation of strain RVY102.
In order to validate the yeast strain RVY102 for screen-
ing of putative 11β-HSD1 inhibitors, carbenoxolone con-
centrations ranging from 0.1 to 3  μM were added to 1 
million RVY102 cells together with 1000  μM cortisone. 
Flow cytometric analyses revealed that increasing con-
centrations of carbenoxolone gradually led to an increase 
of the reporter protein in the population. At a concen-
tration of 3 μM carbenoxolone almost no degradation of 
yEGFP was detected, suggesting complete inhibition of 
the enzyme 11β-HSD1 (Fig. 6).
Improving the sensitivity of the assay systems by inhibiting 
Pdr5p
The relatively high concentration of cortisone required 
to trigger our yeast based assays, when compared to the 
concentrations of carbenoxolone needed to completely 
inhibit 11β-HSD1, raised the question whether the influx 
of cortisone might be limited, and therefore the intra-
cellular cortisone concentration is much lower than 
expected. Consequently, we investigated the intracellular 
availability of cortisone.
Fig. 3 Effect of carbenoxolone (CBX) on 11β-HSD1 dependent 
response in the strains RVY97. 11β-HSD1 dependent yEGFP fluores-
cence of strain RVY97 treated with 250 μM cortisone and increasing 
CBX concentrations. Increasing concentration of carbenoxolone (up 
to 3 μM) led to a decreasing green fluorescence in the yeast popula-
tion indicating a progressive inhibition of 11β-HSD1. The fluores-
cence of untreated cells (no CBX) was set at 1. Data shown represent 
means ± standard deviations of three independent experiments
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Previous studies demonstrated that in yeast, a low 
accumulation of certain steroid molecules due to the 
action of membrane-embedded drug-efflux pumps, can 
strongly affect the functionality of intracellular cascades 
driven by an heterologous GR-hormone complex [25, 31]. 
In the yeast S. cerevisiae, an ATP-binding cassette (ABC) 
transporter, Pdr5p, is able to decrease accumulation of 
certain steroids, thus changing cellular responses caused 
by GR-ligand complexes [25]. Pdr5p has many different 
steroid and non-steroid substrates and tends to protect 
the cells from an improper accumulation of undesired 
molecules [32–34]. The null mutants of this transporter 
allow accumulation of glucocorticoids in cells and maxi-
mal activation of the heterologous GR. There is evidence 
that dexamethasone, a synthetic equivalent of cortisol, 
is a substrate of the transporter Pdr5p [25]; therefore a 
possible recognition and excretion of cortisone by Pdr5p 
was investigated. The expression and activity of Pdr5p 
in strains RVY97 and RVY102, respectively, was studied 
using treatment with 5 μM Rhodamine 6G, a well-known 
target of Pdr5p [34]. Through accumulation of this spe-
cific dye within yeast cells, it is possible to get indications 
about the activity of this transporter. To confirm that 
accumulation of Rhodamine 6G is limited due to Pdr5p 
activity, the Pdr5p inhibitor FK506 [35] was added to the 
cells leading to a strong intracellular accumulation of the 
dye (Fig.  7). Those experiments demonstrated the pres-
ence of significant amounts of active transporter mol-
ecules Pdr5p in our assay strains.
Next, we examined the green fluorescent output of 
strains RVY97 and RVY102 in the presence of 10 μg/ml 
FK506 and upon treatment with different concentrations 
of cortisone. Addition of FK506 dramatically improved 
the sensitivity of the assay strains to cortisone. In fact, 
hormone concentrations up to 60 times lower than used 
before caused equivalent responses of the RVY97 and 
RVY102 strains, when the Pdr5p transporter was not 
active (Fig.  8). These results strongly suggest that corti-
sone is a substrate of the Pdr5p transporter.
Membrane transporters, such as Pdr5p in yeast, can 
impact on whole cell screening assays by, as shown here, 
limiting the accumulation of effector molecules inside 
the cells. Therefore, monitoring activity of these trans-
porter molecules can be of crucial importance for the 
Fig. 4 Schematic representation of the screening system RVY102. a Cortisone added to the growth medium enters RVY102 cells and is reduced 
to cortisol by the enzyme 11β-HSD1. The active complex formed by binding of cortisol to GR triggers expression of the TEV protease which binds 
to its cleavage site and cuts the reporter fluorescent protein that then undergoes degradation. Presence of an 11β-HSD1 inhibitor will stabilize the 
reporter protein. b Graphic representation of the reporter fusion protein expressed in strain RVY102. The fusion protein consists of the red tandem 
dimer (td) Tomato, the TEV recognition site, an N-degron destabilizing sequence, the SF3b155381–424 protein domain and the yeast enhanced green 
fluorescent protein (yEGFP). Once expressed, the TEV protease cuts at its cleavage site on the reporter protein, leading to exposure of the N-degron 
sequence and degradation of yEGFP. The TEV recognition sequence and the destabilizing amino acid (phenylalanine) are shown
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development of efficient whole cell screening assays—
essential tools in the early stages of drug development.
For a final validation of the assays, FK506-treated 
strains RVY97 and RVY102 were incubated with tan-
shinone IIA, a natural steroid-like compound originally 
extracted from the roots of Salvia miltiorrhiza and 
recently identified as inhibitor of the human enzyme 11β-
HSD1 [36].
FK506-treated yeast strain RVY97 was incubated with 
4  μM cortisone and increasing concentrations of tan-
shinone IIA, ranging from 0.1 to 30  μM. After 6  h of 
incubation, yEGFP fluorescence decreases gradually with 
increasing concentration of tanshinone IIA indicating 
progressive inhibition of the activity of human 11β-HSD1 
(Fig. 9a).
Similar results were obtained when incubating the 
FK506-treated strain RVY102 with cortisone and increas-
ing concentrations of tanshinone IIA, ranging from 0.1 to 
60 μM (Fig. 9b). The gradual increase of the yEGFP signal 
with increasing concentrations of tanshinone IIA indi-
cates a progressive inhibition of 11β-HSD1. Those results 
confirm (a) the inhibitory effect of tanshinone IIA on 
Fig. 5 Effect of cortisone on the yEGFP degradation in yeast strain RVY102. a Increased cortisone concentrations cause the expression of TEV pro-
tease in a time and concentration dependent manner. The TEV protease acts on the reporter protein construct causing degradation of the yEGFP. At 
both time points tested the yEGFP degradation signal in the cortisone-treated cells was increasing with increasing concentrations of cortisone. The 
treated RVY102 population was analyzed by flow cytometry (10,000 events) and the results are expressed in percentage of RVY102 cells showing 
loss of green fluorescence due to yEGFP degradation. In all the samples analysed the tdTomato fluorescence was constant and not affected by 
the treatment with cortisone. Data shown represent means ± standard deviations of three independent experiments. b RVY102 yeast population 
treated with DMSO and 1000 μM cortisone. Pictures acquired 6 h upon initiation of the treatment with cortisone showed degradation of yEGFP in 
part of the population (iii), while the tdTomato signal is constant in both treated and untreated cells (ii)
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human 11β-HSD1, and (b) the validity of our yeast-based 
assays for 11β-HSD1 inhibitor screening campaigns.
Conclusions
Intracellular glucocorticoid levels play a relevant role 
in the pathogenesis of metabolic diseases such as obe-
sity and metabolic syndrome. Moreover, high levels 
of active glucocorticoids in skin have been associated 
with impaired collagen metabolism and reduced wound 
healing processes in diabetic and elderly individuals. 
Therefore inhibitors of 11β-HSD1, the main enzyme 
responsible for the activation of glucocorticoids at intra-
cellular level, have been proposed as crucial compounds 
for the treatment of these conditions and for develop-
ment of skin care products that regulate skin homeo-
stasis. Many strategies to find specific inhibitors for this 
enzyme have been developed, but only a few molecules 
have been identified. Among other reasons, this might 
be due to the fact that the screening of large libraries of 
small molecules and the identification of pharmaceuti-
cally active candidates need very efficient assay systems, 
often difficult to establish, or whose development is very 
cost- and labour intense.
The yeast S. cerevisiae has become an important eukar-
yotic host organism for the construction of screening 
assays using heterologous target enzymes. This work 
describes the construction of two yeast strains RVY97 
and RVY102, functionally expressing the human enzyme 
11β-HSD1. The reductase activity of the enzyme on cor-
tisone is efficiently connected with a positive or negative 
fluorescent signal. The dependency of the output signal 
on different cortisone concentrations has been demon-
strated and its specificity confirmed through testing of 
the appropriate corresponding control strains, lacking 
the 11β-HSD1 construct.
During the development of the technology possible 
causes influencing the sensitivity of the assays to corti-
sone were considered and the involvement of the yeast 
drug efflux machinery on the intracellular accumulation 
of cortisone was demonstrated. The ABC transporter 
Pdr5p pumps out cortisone, thus preventing its accumu-
lation inside the yeast cells. The inhibition of this trans-
porter, with FK506, significantly increases the sensitivity 
of the assays.
In order to analyse the suitability of the assay technol-
ogy for screening candidate 11β-HSD1 inhibitors, the 
effects of carbenoxolone and tanshinone IIA, two known 
11β-HSD1 inhibitors, were investigated in both RVY97 
and RVY102 strains. The results clearly show that in 
both assays the downstream reporter systems responded 
effectively and with high sensitivity to increasing inhibi-
tor concentrations. A nearly complete inhibition of the 
human 11β-HSD1 enzyme after treatment with the 
respective highest concentrations of carbenoxolone and 
tanshinone IIA was observed.
The yeast-based screening systems described here rep-
resent a valid alternative to currently available assays for 
screening of 11β-HSD1 inhibitors that are mainly based 
on the use of liver microsomes as source of enzyme, and 
detection of cortisone and cortisol through liquid chro-
matography–mass spectrometry [20]. Both yeast assay 
strains developed, RVY97 and RVY102, are efficient and 
adaptable primary assay systems for the first steps of a 
drug discovery process that aims at selecting cell perme-
able compounds with inhibitory activity for human 11β-
HSD1. Due to the nature of the assay certain intrinsic 
limitations have to be considered. Each compound that 
displays inhibitory effects somewhere within the assay 
chain (11β-HSD1, GR, GREs, TEV protease) will pass 
the first screening gate. In addition, compounds acting 
on 11β-HSD1 may well be active also on 11β-HSD2, a 
clearly unwanted off-target effect. To minimize operating 
expenses due to follow-up of inhibitory molecules of low 
interest, we propose to run potential hits through one of 
the classical cell- or microsome-based assays. Time and 
effort of such tightly focused secondary assays will be 
Fig. 6 Effect of carbenoxolone (CBX) on 11β-HSD1 dependent 
response in the strains RVY102. 11β-HSD1 dependent yEGFP fluores-
cence of strain RVY102 treated with 1000 μM cortisone and increas-
ing CBX concentrations. Increasing concentration of carbenoxolone 
improved the stability of yEGFP in the yeast population indicating a 
progressive loss of enzyme activity. Cells treated with 1000 μM corti-
sone and 3 μM carbenoxolone showed a fluorescence comparable to 
the one of the untreated population (DMSO) indicating a complete 
absence of yEGFP degradation. tdTomato fluorescence was maxi-
mum and constant in all samples analysed and was not affected by 
treatments with cortisone and carbenoxolone (not shown). For data 
normalization details see “Methods” section. Data shown represent 
means ± standard deviations of three independent experiments
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easier manageable than entire screening campaigns with 
such delicate mammalian cell-screening systems. The 
selected candidates can then be used as lead compounds 
for the generation of chemically-related molecules with 
(a) stronger inhibitory effects against the target enzyme, 
(b) improved metabolic half-life, and (c) low selectivity 
for other relevant biological targets in order to minimize 
putative off-target effects.
Fig. 7 Rhodamine 6G accumulates in yeast cells upon Pdr5p inhibition. Rhodamine 6G accumulation in RVY97 (a) and RVY102 (b) yeast strains 
treated or not treated with 10 μg/ml FK506, a known inhibitor of Pdr5p. Each experiment was performed at least three independent times with 
similar results. The figure represents a single result of the replicates
Fig. 8 Effects of FK506 on RVY97 and RVY102 assays functionality. Both RVY97 (a) and RVY102 (b) assays have been tested with or without FK506 
at different concentrations of cortisone. In both assays an increased sensitivity to cortisone in presence of the Pdr5p inhibitor is shown. Each experi-
ment was performed at least three independent times with similar results. The figure represents a single result of the replicates
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Moreover, in recent years the use of yeast-based assays 
in drug discovery processes has been a driving force for 
the development of innovative hit-finding approaches 
based on synthetic biology platforms [37]. Advanced 
combinatorial genetic approaches in baker’s yeast allow 
for the reconstruction of complex biosynthetic pathways 
[38]. This enables the yeast cell to synthesise a large vari-
ety of chemical scaffolds which, through efficient assay 
systems, can be directly screened at intracellular level. 
Here we describe two yeast assay strains, RVY97 and 
RVY102 that can be easily adapted to be part of a syn-
thetic biology platform in which a diversity of chemical 
scaffolds is synthetized and immediately screened for 
activity against the target enzyme 11β-HSD1. Molecules 
that exert inhibitory activity on 11β-HSD1 will cause a 
specific intracellular variation of fluorescence thus allow-
ing the identification of those cells that are producing the 
inhibitor(s). Fluorescence activated cell sorting (FACS) 




All chemicals used in this work were purchased from 
Sigma Aldrich (St. Louis, MO, USA).
Strain construction and growth conditions
All S. cerevisiae strains constructed in this work (Table 1) 
derive from the S150-2B strain (MATa, his3-Δ1, leu2-3 
112, trp1-289, ura3-52). Yeast precultures were grown in 
YP medium plus 2  % glucose (YPD) at 30  °C. The inte-
gration plasmids carrying the construct GRE-yEGFP and 
GRE-TEV were provided by Evolva SA. The TEV and 
yEGFP genes are under the control of a 3xGRE + CYC1-
TATA promoter that efficiently activates downstream 
reporter constructs in yeast upon binding the glucocor-
ticoid receptor [39, 40]. In RVY97 and RVY102 strains, 
the respective GRE-GFP and GRE-TEV constructs were 
integrated as a single copy into the ECM3 locus of chro-
mosome XV of the yeast genome. Positive transformants 
were selected on YPD agar plates containing Hygromycin 
Fig. 9 Effect of tanshinone IIA (TNIIA) on 11β-HSD1 dependent response in the strains RVY97 and RVY102, treated with FK506. a 11β-HSD1 
dependent yEGFP fluorescence of strain RVY97 treated with 4 μM cortisone and with increasing TNIIA concentrations. Increasing concentra-
tions of TNIIA led to a drop of yEGFP fluorescence in the yeast population indicating a progressive loss of 11β-HSD1 activity. The fluorescence of 
untreated cells (no TNIIA) was set at 1. b 11β-HSD1 dependent yEGFP fluorescence of strain RVY102 treated with 32 μM cortisone and increasing 
TNIIA concentrations. Increasing concentrations of tanshinone improved the stability of yEGFP in the yeast population due to the loss of 11β-
HSD1 activity. Cells treated with 32 μM cortisone and 60 μM TNIIA showed a fluorescent signal comparable to the one of the untreated population 
(DMSO) indicating a nearly complete absence of yEGFP degradation. tdTomato fluorescence was constant in all samples analysed, and it was not 
affected by treatments with cortisone and TNIIA (not shown). For data normalization details see “Methods” section. Data shown in a and b represent 
means ± standard deviations of three independent experiments
Table 1 Genotypes of the yeast strains assembled in this work
Strain Genotype
RVY97 S1502B-ECM3::pCYC 3xGRE-yEGFP-tADH1 loxP-HygR-loxP [HSD11B1-URA3-2μ] [Nr3c1-TRP1-2μ]
RVY102 S1502B-ECM3::pCYC3xGRE-TEV-tADH1 loxP-HygR-loxP KIN1::GAL1-Degron-tADH1 loxP-NatR-loxP [HSD11B1-URA3-2μ] [Nr3c1-TRP1-2μ]
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(200  μg/ml). In the RVY102 assay strain, the N-degron 
fluorescent reporter protein construct (Evolva SA), con-
trolled by GAL1 promoter was integrated as a single copy 
into the genome at the KIN1 locus of chromosome IV. 
The positive transformants were selected on YPD agar 
plates containing Nourseothricin (1 mg/ml). All integra-
tion processes were carried out using the lithium acetate 
transformation protocol [41] and successful integration 
confirmed by PCR. Two plasmids carrying the murine 
Nr3c1 [GenBank: NM_008173] cDNA and the wild type 
HSD11B1 [GenBank: NM_005525] human cDNA codify-
ing for GR and 11β-HSD1 respectively were provided by 
Evolva SA. Both sequences were amplified by PCR and 
cloned via TA cloning in pYES 2.1 (invitrogen) down-
stream of the GAL1 promoter. The HSD11B1 cDNA was 
cloned without stop codon and in frame with a sequence 
coding for a polyhistidine tag. The GAL1-HSD11B1 
expression cassette was then amplified by PCR from the 
pYES 2.1 vector and sub-cloned into a plasmid with a 
TRP1 auxotrophic marker (pEVE2113) whereas Nr3c1 
was kept in the pYES 2.1 (URA3). The transformation of 
both ectopic plasmids carrying the Nr3c1 and HSD11B1 
cDNAs was performed using the lithium acetate trans-
formation protocol. Positive clones were selected on 
SD agar plates (2  % glucose) lacking uracil and trypto-
phan for double plasmid selection. All the genetic con-
structs used for strain construction were confirmed by 
sequencing.
All assay experiments with strains RVY97 and RVY102 
were carried out in SD medium (2  % glucose) without 
uracil and tryptophan for 24 h and then washed and re-
suspended in SD medium (2  % galactose) without ura-
cil and tryptophan for induction of GR and 11β-HSD1 
expression.
Validation of the assays with carbenoxolone
Yeast strains were maintained for 24 h in 2 % glucose SD 
medium without uracil and tryptophan. After 24  h, the 
cells were diluted to an optical density measured at a 
wavelength of 600 nm (OD600) of 0.1 in 2 % galactose SD 
medium lacking uracil and tryptophan. The cultures were 
grown for an additional 18  h (about three duplications) 
in galactose to induce 11β-HSD1, GR and the N-Degron 
fluorescent fusion protein expression and then divided 
into 3  ml subcultures. Cortisone was added to the cul-
tures from a 28  mM stock solution in DMSO to the 
required concentrations. At different time points the cells 
were collected, resuspended in 1  ×  PBS and analysed 
using a FACSCalibur flow cytometer from Becton Dick-
son (San Jose, CA, USA). Every experiment was repeated 
independently at least three times.
The specificity of the signal upon treatment with cor-
tisone was confirmed with strains in which the plasmids 
carrying the 11β-HSD1 expression cassette were replaced 
by the equivalent empty plasmids. Except for the missing 
11β-HSD1 expression construct, the strains were identi-
cal to the two parental assay strains RVY97 and RVY102. 
In the validation of the assays the 11β-HSD1 inhibi-
tor carbenoxolone (CBX) (stock solution 1  mM/water) 
was added to 106 cells together with cortisone to reach 
a final concentration of 0.1, 0.3, 1.0 and 3.0 μM, respec-
tively. Cells were incubated for 6 h and after washing in 
1 ×  PBS the samples were analysed by flow cytometry. 
Both RVY97 and RVY102 strains were tested with car-
benoxolone under identical conditions.
Figure 6 shows the green fluorescence of RVY102 sam-
ples treated with 1000 μM cortisone and increasing con-
centration of carbenoxolone (CBX). The percentage of 
yEGFP degradation events obtained upon treatment of 
RVY102 cells with 1000 μM cortisone and no carbenox-
olone was set at 1. This value was used as reference for 
the normalization of the other degradation values. In 
order to get the fluorescence values plotted, the formula 
“fluorescence = 1 − degradation value” was used.
Analysis of yeast fluorescence
250 μl of yeast culture volume were centrifuged and re-
suspended in 500 μl 1 × PBS. Flow cytometric analyses 
were performed using the FACSCalibur instrument. The 
instrument settings were as follows: log forward scatter 
(FSC) E00; log side scatter 2 (SSC) at 458 V, log FL1 fluo-
rescence at 468 V and log FL2 fluorescence at 460 V. The 
yEGFP fluorescence was excited at 488 nm and collected 
through 530/30 nm band-pass filter on the FL1 channel. 
The tdTomato fluorescence was excited at 488  nm and 
collected through 585/42 nm band-pass filter on the FL2 
channel. For multicolour analysis of the strain RVY102, 
fluorescence compensation (FL2 20.8 % FL1) was manu-
ally set using single colour cell controls. The typical 
sampling rate was 200 events/s, and the typical sample 
size was 10,000 cells per measurement. The data were 
analysed with FlowJo vX.0.7 software. For fluorescence 
images the samples were taken at different dilutions and 
examined for green and red fluorescence under the opti-
cal microscope BX41 (Olympus) equipped with FITC 
and TRITC filter sets using a 40x magnification lens and 
an exposure time of 1/3 s.
Rhodamine 6G accumulation and efflux
The strains RVY97 and RVY102 (OD600 of 0.1) were 
incubated in the presence of FK506 (10  μM) or DMSO 
(control) for 20  min followed by incubation with 5  μM 
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Rhodamine 6G for 1 h at 30 °C. 10,000 cells of each popu-
lation were analysed by flow cytometry.
Sensitivity to cortisone in presence of FK506
The 11β-HSD1 assay strains RVY97 and RVY102 were 
tested for the cortisone induced gene transactivation 
after incubation with 10 μM FK506 or DMSO for 20 min 
at 30 °C.
Validation of the assays with tanshinone IIA
RVY97 and RVY102 strains were maintained for 24  h in 
2  % glucose SD medium without uracil and tryptophan. 
After 24 h, the cells were diluted to an OD600 of 0.1 in 2 % 
galactose SD medium lacking uracil and tryptophan. The 
cultures were grown for an additional 18  h (about three 
duplications) in galactose to induce 11β-HSD1, GR and the 
N-degron fluorescent fusion protein expression and then 
divided into 3  ml subcultures containing 106 cells each. 
After treatment with FK506 (10 μM) for 20 min at 30 °C, 
the 11β-HSD1 inhibitor tanshinone IIA (TNIIA) (stock 
solution 500  μM/methanol) was added to RVY97 cells 
together with cortisone (4 μM) to reach a final concentra-
tion of 0.1,1, 3, 6, 10, 30 μM respectively. The yeast strain 
RVY102 after incubation with FK506 (10 μM) for 20 min 
at 30 °C was treated with 32 μM cortisone and tanshinone 
IIA (TNIIA) (stock solution 500  μM/methanol) at final 
concentration of 0.1, 0.3, 1, 3, 10, 30, 60 μM respectively.
Cells were incubated for 6  h and after washing in 
1 × PBS the samples were analysed by flow cytometry.
The normalization of the data shown in Fig. 9a, b was 
performed as described in “Validation of the assays with 
carbenoxolone”.
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